808118-40-3 Roxadustat (FG-4592) AKSci J96601
 
 
Loading Please Wait...
  J96601    
Roxadustat (FG-4592)
, 95%
 
2-(4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid
N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine




IDENTITY
CAS Number:808118-40-3
MDL Number:MFCD20040519
MF:C19H16N2O5
MW:352.34
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:222-225°C
Density:1.4
Refractive Index:1.67
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO 71 mg/mL
Application(s):HIF
Form:Free acid
Research Area:Cancer

REVIEW

 FG-4592 is an orally-available isoquinoline-based inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase for the treatment of anemia and patients with chronic kidney disease. Phase 2 studies indicate that oral administration of FG-4592 three times a week increased mean hemoglobin levels in the first eight weeks, regardless of supplementation with IV or oral iron, or no iron supplementation. FG-4592 is novel in that it allows integration of red blood cell production and efficient iron incorporation simultaneously. Data from Phase 2 trials comparing with epoetin alpha indicate that treatment with FG-4592 alone results in a sustained reduction of total plasma cholesterol levels by an average of 20%, while no reduction was seen with epoetin alpha. In December, 2012, Fibrogen and Astellas Pharma announced the initiation of a Phase 3 clinical development program for the treatment of anemia associated with chronic kidney disease in patients not on dialysis and on dialysis.

REFERENCES
[1]Arend, Michael P.; Flippin, Lee A.; Guenzler-Pukall, Volkmar; Ho, Wen-Bin; Turtle, Eric D.; Du, Xiaohui; Preparation of isoquinolinecarboxamides and their use in mediating hypoxia inducible factor and increasing endogenous erythropoietin. PCT Int. Appl. (2004), WO 2004108681 A1 20041216.
[2] Kang, Xinshan; Long, Wei; Zhang, Jianxi; Hu, Yunyan; Wang, Yinxiang; Preparation and polymorphic forms of an isoquinolylcarbonyl glycine derivative as a prolyl hydroxylase inhibitor. PCT Int. Appl. (2013), WO 2013013609 A1 20130131.
[3] Beuck S, Schänzer W, Thevis M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal. 2012 Nov;4(11):830-45.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of May 6, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives >


PubChem
  @PubMed